Aligos Therapeutics, Inc.
ALGS
$10.09
$0.24662.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.05% | 46.52% | -49.65% | 5.78% | 7.92% |
| Total Depreciation and Amortization | -10.18% | -28.68% | -38.87% | -37.95% | -41.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 209.38% | -183.03% | 253.73% | -137.64% | -125.96% |
| Change in Net Operating Assets | 17.78% | 70.95% | 47.98% | 41.94% | -57.28% |
| Cash from Operations | 12.10% | 0.57% | -2.21% | -16.24% | -21.90% |
| Capital Expenditure | -116.84% | -28.40% | -584.21% | -5.83% | -1.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -200.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8.96% | 141.53% | -140.33% | -167.29% | -154.46% |
| Cash from Investing | -9.15% | 141.31% | -140.64% | -167.60% | -154.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 18.33% | 29.67% | 13.54% | 32.31% | 16.67% |
| Issuance of Common Stock | 471.41% | 467.86% | -97.57% | 2,984.95% | 2,937.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15.29% | 15.63% | -99.60% | 17,091.81% | 17,021.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.31% | 190.50% | -281.67% | -118.90% | -332.37% |